A Study of TAK-071 in People With Parkinson Disease
Public ClinicalTrials.gov record NCT04334317. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral TAK-071 in Parkinson Disease Patients With Cognitive Impairment and an Elevated Risk of Falls
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
It is hoped that TAK-071 will help people with Parkinson's disease to walk with better balance. The main aim of the study is to check if there is a difference in how participants walk after treatment with TAK-071. Another aim is to see if it improves how participants think and remember. At the first visit, the study doctor will check who can take part. Participants who can take part will be picked for 1 of 2 groups by chance. Both groups will have 2 treatments but in a different order. The treatments are TAK-071 tablets or placebo. In this study, a placebo will look like the TAK-071 but will not have any medicine in it. One group will take TAK-071 for 6 weeks, have at least a 3-week break, then take a placebo for 6 weeks. The other group will take a placebo for 6 weeks, have at least a 3-week break, then take TAK-071 for 6 weeks. The participants will not know the order of their 2 treatments, nor will their study doctors. This is to help make sure the results are more reliable. The participants will visit the clinic at the beginning and end of each treatment for a check-up. 14 days after the 2nd treatment, clinic staff will telephone the participants for a final check-up.
Study identification
- NCT ID
- NCT04334317
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 64 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 20, 2020
- Primary completion
- Feb 26, 2023
- Completion
- Feb 26, 2023
- Last update posted
- May 13, 2024
2020 – 2023
United States locations
- U.S. sites
- 21
- U.S. states
- 15
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Collaborative Neuroscience Network, LLC | Garden Grove | California | 92845 | — |
| University of California Irvine Medical Center | Irvine | California | 92697 | — |
| Cedars Sinai Medical Center | Los Angeles | California | 90048 | — |
| Rocky Mountain Movement Disorders Center | Englewood | Colorado | 80113 | — |
| PPD Phase 1 Clinic | Orlando | Florida | 32806 | — |
| Infinity Clinical Research, LLC | Sunrise | Florida | 33351 | — |
| USF Medical Clinic | Tampa | Florida | 33612 | — |
| Augusta University | Augusta | Georgia | 30912 | — |
| Feinberg School of Medicine Northwestern University | Chicago | Illinois | 60611 | — |
| Indiana University Health Neuroscience Center | Indianapolis | Indiana | 46202 | — |
| Quest Research Institute - Hunt - PPDS | Farmington Hills | Michigan | 48334 | — |
| Park Nicollet Health Services | Golden Valley | Minnesota | 55427 | — |
| University of Rochester Medicine - Movement Disorders Unit | Rochester | New York | 14618 | — |
| Neurology Diagnostics, Inc. - ERG - PPDS | Dayton | Ohio | 45459 | — |
| University of Philadelphia | Philadelphia | Pennsylvania | 19107 | — |
| Medical University of South Carolina - PPDS | Charleston | South Carolina | 29425 | — |
| Baylor College of Medicine | Houston | Texas | 77030 | — |
| Central Texas Neurology | Round Rock | Texas | 78681 | — |
| Meridian Clinical Research | Norfolk | Virginia | 23502 | — |
| Evergreen Hospital Medical Center | Kirkland | Washington | 98034 | — |
| Inland Northwest Research | Spokane | Washington | 99202-6290 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04334317, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 13, 2024 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04334317 live on ClinicalTrials.gov.